Andere talen Biofrontera Inc.

Aandelen

BFRI

US09077D2099

Vertraagde tijd Nasdaq Andere beurzen 15:30:09 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,64 ^USD	-1,20%		-1,80%	-40,79%

18/03	Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024
15/03	Biofrontera Inc. rapporteert winstresultaten voor het vierde kwartaal dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03
Biofrontera Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	11/03
Medicus Pharma Names COO	05/03
Biofrontera Inc. announced that it has received $8 million in funding	22/02
BIOFRONTERA AG ANNOUNCES REVISED STRATEGY	21/02
BIOFRONTERA AG, BIOFRONTERA TRANSFERS CLINICAL RESEARCH TO THE U.S.	21/02
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera Ag	20/02
Biofrontera Inc. announced that it expects to receive $8 million in funding	19/02
MORNING BRIEFING - Deutschland/Europa -2-	16/02
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use	05/02
Certain Warrants of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Common Stock of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Stock options of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	11/01
Biofrontera Inc. Terminates MidCap Business Credit Loan Agreement	09/01
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023	09/11
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	09/11
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	10-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Biofrontera Inc.

Aandelen

BFRI

US09077D2099

Andere talen

Filters